OmniAb (OABI) Free Cash Flow (2021 - 2026)
OmniAb (OABI) reported Free Cash Flow of -$5.1 million for Q1 2026, up 68.4% year-over-year from -$3.0 million in Q1 2025, and up 10.59% quarter-over-quarter from -$5.7 million in Q4 2025.
OmniAb (OABI) Free Cash Flow (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Free Cash Flow data on file, last reported at -$5.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$5.1 million, up 68.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.0 million (up 32.11% YoY), and the FY2025 annual result was -$37.0 million, up 6.85% from the prior year.
- Free Cash Flow grew to -$5.1 million in Q1 2026 per OABI's latest filing, from -$5.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $27.5 million in Q1 2023 and troughed at -$17.5 million in Q1 2024.
- A 5-year average of -$4.9 million and a median of -$5.3 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow plunged 333.79% in 2022, then surged 200.73% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$3.6 million in 2022, then sank by 170.81% to -$9.8 million in 2023, then jumped by 78.28% to -$2.1 million in 2024, then slumped by 168.07% to -$5.7 million in 2025, then gained by 10.59% to -$5.1 million in 2026.
- Business Quant data shows OABI's Free Cash Flow at -$5.1 million in Q1 2026, -$5.7 million in Q4 2025, and -$9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | -5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.08 Mn |
| Mar 31, 2026 | -5.08 Mn |
| Dec 31, 2025 | -5.68 Mn |
| Dec 31, 2025 | -5.68 Mn |
| Sep 30, 2025 | -9.95 Mn |
| Sep 30, 2025 | -9.95 Mn |
| Jun 30, 2025 | -5.31 Mn |
| Jun 30, 2025 | -5.31 Mn |
| Mar 31, 2025 | -16.08 Mn |
| Mar 31, 2025 | -16.08 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Sep 30, 2024 | -8.25 Mn |
| Sep 30, 2024 | -8.25 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Mar 31, 2024 | -17.50 Mn |
| Mar 31, 2024 | -17.50 Mn |
| Dec 31, 2023 | -9.76 Mn |
| Dec 31, 2023 | -9.76 Mn |